Navigation Links
Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
Date:3/30/2009

es on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Publication of Shire plcs Annual Report 2008
2. Shires Project Playground Gives Boost to Philadelphia
3. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
4. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
5. Shire Announces Opening of Office in Japan
6. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
7. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
8. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
9. Shire plc: Change to Directors Details
10. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
11. Shires New Product Portfolio Delivers Strong Quarterly Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... / Rootstown, OH (PRWEB) January 22, 2015 ... platform, announced today that it has received AOAC-PTM Certifications for ... O1O3, O111, O121, and O145; collectively referred to as STEC ... O157, at 1 colony forming unit (cfu) per 325 g ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 zFlo Motion ... pleased to announce an exciting product from a new partner. ... analysis solutions over the past 15 years, with offerings in ... recently, their 3D IMU system (inertial measurement unit), iSen, is ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 23D Motion Capture Just Got Easy 2Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... 2 Randomized Study Under Consideration, ROCKVILLE, Md., ... a clinical-stage pharmaceutical company developing,therapeutics for the treatment ... has met the primary endpoint for the efficacy ... MKC-1 in combination with pemetrexed,(Alimta(R)) in non-small cell ...
... NANJING, China, Nov. 10 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical,Group ... supplier of branded generic,pharmaceuticals and innovative anti-cancer pharmaceuticals ... participation in the Morgan,Stanley 7th Annual Asia Pacific ... Mandarin Oriental Singapore on November 11-13, 2008., ...
... Partners will provide partnership for identifying expansion and investment opportunities. ... ... (PRWEB) November 10, 2008 -- World Trade Center Dulles Airport ... seeking to access global markets, today announced its business launch ...
Cached Biology Technology:EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial 2EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial 3Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008 2Former NASDAQ International President Among Execs Launching Firm to Access Global Markets 2Former NASDAQ International President Among Execs Launching Firm to Access Global Markets 3
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor technology, ... such as Intel, Jabra, Atlas, and Scosche to develop ... products will be showcased at CES 2015, taking place ... "Our partners choose PerformTek biometrics, because ...
(Date:12/11/2014)... Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... addition of the "Biometrics Market in India 2015-2019" ... major trend emerging in this market is the adoption ... than one characteristic of an individual for verification and ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for a ... for this $50 million capital project is part of a ... The medical education building will be located ... adjacent to 525@vine in Wake Forest Innovation Quarter. Construction will ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... oyster native to the West Coast could face a double ... research from the University of California, Davis, Bodega Marine Laboratory. ... Proceedings of the Royal Society B . Invasive snails ... snails were raised under ocean conditions forecast for the end ...
... Minn. , Jan. 15, 2014 MedNet Solutions ... study management systems, is pleased to announce that the latest ... released to the iMedNet user community.  iMedNet ... eClinical platform ideally suited to Sponsors and CROs wanting to ...
... news release is available in German . ... economists and politicians usually call a win-win situation: a relationship between ... acacia plants and the ants that live on them is an ... of food bodies and nectar as well as hollow thorns which ...
Cached Biology News:Acidification, predators pose double threat to oysters 2MedNet Solutions Announces Latest Release Of Its Innovative iMedNet EDC eClinical Solution 2Ants protect acacia plants against pathogens 2Ants protect acacia plants against pathogens 3
Biotin d anti-mouse Tim-1...
Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
Anti-20S proteasome subunits alpha 1, 2, 3, 5, 6 & 7, clone MCP231 Immunogen: Dinitrophenylated proteasomes Molecular Weight: 29 and 32 kDa....
Anti-ADP-Ribosylation Factor 1, clone 3F1 Immunogen: Synthetic peptide corresponding to the C-terminal amino acid sequence of human ARF1. Available Date: 38495...
Biology Products: